PROFILE study was a multicenter, open-label, biomarker-stratified, randomized controlled trial that included adults with newly diagnosed active Crohn’s disease (Harvey-Bradshaw Index ≥ 7, either elevated C-reactive protein or fecal calprotectin or both, and endoscopic evidence of active inflammation) that received either top-down or accelerated step-up treatment [24]. The gene discussed is CRP; the disease is Crohn disease.